Abeona Therapeutics (LTS:0H7R) ROCE % : -33.77% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Abeona Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Abeona Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2024 was -33.77%.

Abeona Therapeutics ROCE % Historical Data

The historical data trend for Abeona Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics ROCE % Chart

Abeona Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-54.52

-94.40

-65.26

-100.49

-83.30

Abeona Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-121.80	-215.83	37.66	-106.39	-33.77

Abeona Therapeutics ROCE % Calculation

Abeona Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-59.526	/	( ( (64.002 - 13.422)	+	(108.931 - 16.587) )	/ 2 )
	=	-59.526	/	( (50.58	+	92.344)	/ 2 )
	=	-59.526	/	71.462
	=	-83.30 %

Abeona Therapeutics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-32.844	/	( ( (120.592 - 18.422)	+	(108.931 - 16.587) )	/ 2 )
	=	-32.844	/	( ( 102.17	+	92.344 )	/ 2 )
	=	-32.844	/	97.257
	=	-33.77 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Abeona Therapeutics (LTS:0H7R) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Abeona Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abeona Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (LTS:0H7R) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ABEO:USA PCJ:Germany PCJ:Germany

Address

6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103

Website

https://www.abeonatherapeutics.com

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Headlines

No Headlines